Home › Companies › RECURSION PHARMACEUTICALS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and RECURSION PHARMACEUTICALS INC.’s Form 8-K, filed June 18, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 18, 2025: 5 items on RECURSION PHARMACEUTICALS INC.’s Form 8-K, filed June 18, 2025: 3 elected · 2 approved.
Meeting of November 12, 2024: 1 item on RECURSION PHARMACEUTICALS INC.’s Form 8-K, filed November 13, 2024: 1 approved.
Notable dissent: 1 director (17.4% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore RECURSION PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are RECURSION PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 18, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. RECURSION PHARMACEUTICALS INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Zachary Bogue, J.D. | 242,298,743 | -- | -- | 3,971,237 | 93,369,778 | 98% | Elected | — |
| Elect Director: Zavain Dar | 203,315,209 | -- | -- | 42,954,771 | 93,369,778 | 83% | Elected | — |
| Elect Director: Robert Hershberg, M.D. Ph.D. | 233,487,438 | -- | -- | 12,782,542 | 93,369,778 | 95% | Elected | — |
| 2. Advisory resolution to approve executive compensation, as disclosed in the Proxy Statement | 239,911,332 | 3,242,536 | 3,116,112 | -- | 93,369,778 | 99% | Approved | — |
| 3. Appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2025 | 334,613,329 | 1,968,162 | 3,058,267 | -- | -- | 99.4% | Approved | — |
Source: RECURSION PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 18, 2025 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. To approve the issuance of shares of Class A Common Stock of Recursion in connection with the Transaction for purposes of complying with the applicable provisions of the Nasdaq Listing Rules | 250,943,702 | -- | 2,003,579 | 568,667 | 0 | 99.8% | Approved | — |
Source: RECURSION PHARMACEUTICALS INC., Form 8-K, filed with the SEC on November 13, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
301 asset managers disclosed a vote on at least one RECURSION PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of RECURSION PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held June 18, 2025.
Combines 7 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Robert Hershberg, M.D. Ph.D.
RECURSION PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Robert Hershberg, M.D. Ph.D.”): 233,487,438 for, 12,782,542 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, the Company's stockholders voted on the following proposals, each of which is described in more detail in the Company's definitive Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 28, 2025 (the "Proxy Statement"): Proposal 1: T…”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 56 asset managers below reported 2,178,675 for, 2,084,117 withheld, 1,219,347 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 489,488 | 0 | 0 | 1,043,951 | Mixed |
| BlackRock | 0 | 0 | 1,100,917 | 0 | Abstain |
| State Street | 375,282 | 0 | 0 | 22 | For |
| Equitable | 4,890 | 0 | 0 | 283,246 | Withhold |
| Fidelity | 152,370 | 0 | 0 | 109,153 | Mixed |
| Lincoln Financial | 238,444 | 0 | 0 | 207 | For |
| Charles Schwab | 0 | 0 | 0 | 225,068 | Withhold |
| ARK Venture Fund | 199,568 | 0 | 0 | 0 | For |
| WisdomTree | 149,993 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 128,445 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 115,547 | Withhold |
| WESMARK FUNDS | 111,200 | 0 | 0 | 0 | For |
| First Trust | 103,157 | 0 | 0 | 0 | For |
| Pacific Life | 0 | 0 | 0 | 78,245 | Withhold |
| Bridge Builder Trust | 0 | 0 | 49,449 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 45,753 | 0 | Abstain |
| Global X | 0 | 0 | 0 | 42,251 | Withhold |
| DWS | 0 | 0 | 0 | 39,068 | Withhold |
| SEI Exchange Traded Funds | 0 | 0 | 0 | 34,446 | Withhold |
| SEI | 0 | 0 | 0 | 34,000 | Withhold |
| Columbia Threadneedle | 32,768 | 0 | 0 | 0 | For |
| Guggenheim | 30,789 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 28,434 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 27,917 | 0 | 0 | 0 | For |
| Calvert | 26,030 | 0 | 0 | 0 | For |
Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).
Meeting held June 18, 2025.
Combines 6 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Zachary Bogue, J.D.
RECURSION PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Zachary Bogue, J.D.”): 242,298,743 for, 3,971,237 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, the Company's stockholders voted on the following proposals, each of which is described in more detail in the Company's definitive Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 28, 2025 (the "Proxy Statement"): Proposal 1: T…”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 56 asset managers below reported 5,196,752 for, 271,278 withheld, 14,109 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,533,439 | 0 | 0 | 0 | For |
| BlackRock | 1,100,917 | 0 | 0 | 0 | For |
| State Street | 375,304 | 0 | 0 | 0 | For |
| Equitable | 44,922 | 0 | 0 | 243,214 | Mixed |
| Fidelity | 261,523 | 0 | 0 | 0 | For |
| Lincoln Financial | 238,444 | 0 | 0 | 207 | For |
| Charles Schwab | 225,068 | 0 | 0 | 0 | For |
| ARK Venture Fund | 199,568 | 0 | 0 | 0 | For |
| WisdomTree | 149,993 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 128,445 | 0 | 0 | 0 | For |
| Northern Trust | 115,547 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 111,200 | 0 | 0 | 0 | For |
| First Trust | 103,157 | 0 | 0 | 0 | For |
| Pacific Life | 78,245 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 49,449 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 45,753 | 0 | 0 | 0 | For |
| Global X | 42,251 | 0 | 0 | 0 | For |
| DWS | 39,068 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 34,446 | 0 | 0 | 0 | For |
| SEI | 34,000 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 32,768 | 0 | 0 | 0 | For |
| Guggenheim | 30,789 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 28,434 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 27,917 | 0 | 0 | 0 | For |
| Calvert | 26,030 | 0 | 0 | 0 | For |
Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).
Meeting held June 18, 2025.
Combines 6 wordings of this item as funds reported it.
83% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Zavain Dar
RECURSION PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Zavain Dar”): 203,315,209 for, 42,954,771 withheld, per its Form 8-K filed June 18, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, the Company's stockholders voted on the following proposals, each of which is described in more detail in the Company's definitive Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 28, 2025 (the "Proxy Statement"): Proposal 1: T…”
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 56 asset managers below reported 3,431,734 for, 2,016,706 withheld, 33,699 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,533,418 | 0 | 0 | 21 | For |
| BlackRock | 1,100,917 | 0 | 0 | 0 | For |
| State Street | 1,061 | 0 | 0 | 374,243 | Withhold |
| Equitable | 44,922 | 0 | 0 | 243,214 | Mixed |
| Fidelity | 261,523 | 0 | 0 | 0 | For |
| Lincoln Financial | 0 | 0 | 0 | 238,651 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 225,068 | Withhold |
| ARK Venture Fund | 199,568 | 0 | 0 | 0 | For |
| WisdomTree | 0 | 0 | 0 | 149,993 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 128,445 | Withhold |
| Northern Trust | 0 | 0 | 0 | 115,547 | Withhold |
| WESMARK FUNDS | 0 | 0 | 0 | 111,200 | Withhold |
| First Trust | 0 | 0 | 0 | 103,157 | Withhold |
| Pacific Life | 78,245 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 49,449 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 45,753 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 42,251 | Withhold |
| DWS | 0 | 0 | 0 | 39,068 | Withhold |
| SEI Exchange Traded Funds | 0 | 0 | 0 | 34,446 | Withhold |
| SEI | 0 | 0 | 0 | 34,000 | Withhold |
| Columbia Threadneedle | 32,768 | 0 | 0 | 0 | For |
| Guggenheim | 0 | 0 | 0 | 30,789 | Withhold |
| AMERICAN BEACON FUNDS | 28,434 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 27,917 | Withhold |
| Calvert | 0 | 0 | 0 | 26,030 | Withhold |
Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).
Meeting held November 12, 2024.
Combines 3 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: To approve the issuance of shares of Class A Common Stock of Recursion Pharmaceuticals, Inc. ("Recursion") in connection with Recursion's acquisition of the entire issued and to be issued share capital of Exscientia plc pursuant to a scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006, for purposes of complying with the applicable provisions of the Nasdaq Listing Rules (the "Recursion Share Issuance Proposal").
RECURSION PHARMACEUTICALS INC.’s own tally for this item (“1. To approve the issuance of shares of Class A Common Stock of Recursion in connection with the Transaction for purposes of complying with the applicable provisions of the Nasdaq Listing Rules”): 250,943,702 for, 568,667 withheld — passed, per its Form 8-K filed November 13, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 1 was approved.”
Support: 99.8% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 58 asset managers below reported 15,705,757 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,030,158 | 0 | 0 | 0 | For |
| State Street | 1,688,092 | 0 | 0 | 0 | For |
| BlackRock | 1,114,022 | 0 | 0 | 0 | For |
| Fidelity | 1,037,395 | 0 | 0 | 0 | For |
| TIAA | 333,538 | 0 | 0 | 0 | For |
| Equitable | 276,795 | 0 | 0 | 0 | For |
| Charles Schwab | 274,859 | 0 | 0 | 0 | For |
| Lincoln Financial | 219,608 | 0 | 0 | 0 | For |
| Dimensional | 208,147 | 0 | 0 | 0 | For |
| Russell Investments | 170,223 | 0 | 0 | 0 | For |
| ARK Venture Fund | 125,321 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 113,072 | 0 | 0 | 0 | For |
| Northern Trust | 112,470 | 0 | 0 | 0 | For |
| Neuberger Berman | 111,595 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 111,200 | 0 | 0 | 0 | For |
| Pacific Life | 87,521 | 0 | 0 | 0 | For |
| JPMorgan | 65,868 | 0 | 0 | 0 | For |
| SEI | 55,151 | 0 | 0 | 0 | For |
| John Hancock | 47,927 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 46,258 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 43,512 | 0 | 0 | 0 | For |
| Global X | 43,317 | 0 | 0 | 0 | For |
| DWS | 38,347 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 34,085 | 0 | 0 | 0 | For |
| AuguStar | 32,111 | 0 | 0 | 0 | For |
Showing the 25 largest of 58 asset managers. All 58 are in the interactive database (link above).
Meeting held November 12, 2024.
Combines 2 wordings of this item as funds reported it.
87% of fund votes cast · no official result
Description as filed by funds: To approve any motion to adjourn the special meeting of stockholders of Recursion (the "Recursion Special Meeting") to another time or place, if necessary or appropriate, including to solicit additional proxies if there are insufficient votes at the time of the Recursion Special Meeting to approve the Recursion Share Issuance Proposal.
The 57 asset managers below reported 13,671,720 for, 2,001,388 against, 32,111 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,030,158 | 0 | 0 | 0 | For |
| State Street | 3,864 | 1,684,228 | 0 | 0 | Against |
| BlackRock | 1,114,022 | 0 | 0 | 0 | For |
| Fidelity | 904,022 | 133,373 | 0 | 0 | Mixed |
| TIAA | 333,538 | 0 | 0 | 0 | For |
| Equitable | 276,795 | 0 | 0 | 0 | For |
| Charles Schwab | 274,859 | 0 | 0 | 0 | For |
| Lincoln Financial | 57,708 | 161,900 | 0 | 0 | Mixed |
| Dimensional | 208,147 | 0 | 0 | 0 | For |
| Russell Investments | 170,223 | 0 | 0 | 0 | For |
| ARK Venture Fund | 125,321 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 113,072 | 0 | 0 | 0 | For |
| Northern Trust | 112,470 | 0 | 0 | 0 | For |
| Neuberger Berman | 111,595 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 111,200 | 0 | 0 | 0 | For |
| Pacific Life | 87,521 | 0 | 0 | 0 | For |
| JPMorgan | 65,868 | 0 | 0 | 0 | For |
| SEI | 55,151 | 0 | 0 | 0 | For |
| John Hancock | 47,927 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 46,258 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 43,512 | 0 | 0 | 0 | For |
| Global X | 43,317 | 0 | 0 | 0 | For |
| DWS | 38,347 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 34,085 | 0 | 0 | 0 | For |
| AuguStar | 0 | 0 | 32,111 | 0 | Abstain |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
Meeting held June 18, 2025.
Combines 9 wordings of this item as funds reported it.
99% Approved · of votes cast
Prior year: 98.5% for (June 3, 2024 meeting) ▲ 0.2 pts
Description as filed by funds: Advisory vote to approve executive compensation as disclosed in the 2025 Proxy Statement.
RECURSION PHARMACEUTICALS INC.’s own tally for this item (“2. Advisory resolution to approve executive compensation, as disclosed in the Proxy Statement”): 239,911,332 for, 3,242,536 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of RECURSION PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (8 managers, 14,806,861 for, 3,161 against, 1,000 abstained).
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,533,439 | 0 | 0 | 0 | For |
| BlackRock | 1,100,917 | 0 | 0 | 0 | For |
| State Street | 374,830 | 474 | 0 | 0 | For |
| Equitable | 288,136 | 0 | 0 | 0 | For |
| Fidelity | 261,523 | 0 | 0 | 0 | For |
| Lincoln Financial | 238,651 | 0 | 0 | 0 | For |
| Charles Schwab | 225,068 | 0 | 0 | 0 | For |
| ARK Venture Fund | 199,568 | 0 | 0 | 0 | For |
| WisdomTree | 149,993 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 128,445 | 0 | 0 | 0 | For |
| Northern Trust | 115,547 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 111,200 | 0 | 0 | 0 | For |
| First Trust | 103,157 | 0 | 0 | 0 | For |
| Pacific Life | 78,245 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 58,014 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 49,449 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 45,753 | 0 | 0 | 0 | For |
| Global X | 42,251 | 0 | 0 | 0 | For |
| DWS | 39,068 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 34,446 | 0 | 0 | 0 | For |
| SEI | 34,000 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 32,768 | 0 | 0 | 0 | For |
| Guggenheim | 30,789 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 28,434 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 27,917 | 0 | 0 | 0 | For |
Fund voting reports, all 57 managers: 5,513,493 for, 2,026 against, 24,634 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Kinnevik AB (publ) | 13,434,171 | 0 | 0 | 0 | For |
| Mubadala Investment Co PJSC | 12,985,927 | 0 | 0 | 0 | For |
| Novo Holdings A/S | 9,665,128 | 0 | 0 | 0 | For |
| Nikko Asset Management Co., Ltd. | 8,476,829 | 0 | 0 | 0 | For |
| Lingotto Investment Management LLP | 3,675,077 | 0 | 0 | 0 | For |
| State Street | 2,380,362 | 703 | 0 | 0 | For |
| BlackRock | 1,861,021 | 0 | 0 | 0 | For |
| Laurion Capital Management LP | 1,547,407 | 0 | 0 | 0 | For |
| MIC Capital Management UK LLP | 1,388,889 | 0 | 0 | 0 | For |
| Northern Trust | 1,299,706 | 0 | 0 | 0 | For |
| Irish Life Investment Managers Ltd. | 1,232,365 | 0 | 0 | 0 | For |
| ARK Investment Management LLC | 948,092 | 0 | 0 | 0 | For |
| Vestmark Advisory Solutions, Inc. | 675,884 | 0 | 0 | 0 | For |
| Liontrust Investment Partners LLP | 595,955 | 0 | 0 | 0 | For |
| Lazard | 583,734 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD OVERSEAS LTD | 510,162 | 0 | 0 | 0 | For |
| CAPITAL FUND MANAGEMENT S.A. | 472,342 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 410,286 | 0 | 0 | 0 | For |
| UBS | 0 | 393,958 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 381,990 | 0 | 0 | 0 | For |
| ROCKEFELLER FINANCIAL LLC | 378,511 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 258,754 | 0 | 0 | 0 | For |
| RBC Capital Markets, LLC | 247,540 | 0 | 0 | 0 | For |
| AllianceBernstein | 243,214 | 0 | 0 | 0 | For |
| Charles Schwab | 226,025 | 0 | 0 | 0 | For |
Institutional-manager reports, all 242 managers: 67,675,121 for, 569,833 against, 300 abstained, 165 not voted, 250 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held June 18, 2025.
Combines 2 wordings of this item as funds reported it.
99.4% Approved · of votes cast
Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for fiscal year ending December 31, 2025.
RECURSION PHARMACEUTICALS INC.’s own tally for this item (“3. Appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2025”): 334,613,329 for, 1,968,162 against — passed, per its Form 8-K filed June 18, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2025 was ratified, with the following votes cast:”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 57 asset managers below reported 5,515,519 for, 0 against, 24,634 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,533,439 | 0 | 0 | 0 | For |
| BlackRock | 1,100,917 | 0 | 0 | 0 | For |
| State Street | 375,304 | 0 | 0 | 0 | For |
| Equitable | 288,136 | 0 | 0 | 0 | For |
| Fidelity | 261,523 | 0 | 0 | 0 | For |
| Lincoln Financial | 238,651 | 0 | 0 | 0 | For |
| Charles Schwab | 225,068 | 0 | 0 | 0 | For |
| ARK Venture Fund | 199,568 | 0 | 0 | 0 | For |
| WisdomTree | 149,993 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 128,445 | 0 | 0 | 0 | For |
| Northern Trust | 115,547 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 111,200 | 0 | 0 | 0 | For |
| First Trust | 103,157 | 0 | 0 | 0 | For |
| Pacific Life | 78,245 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 58,014 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 49,449 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 45,753 | 0 | 0 | 0 | For |
| Global X | 42,251 | 0 | 0 | 0 | For |
| DWS | 39,068 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 34,446 | 0 | 0 | 0 | For |
| SEI | 34,000 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 32,768 | 0 | 0 | 0 | For |
| Guggenheim | 30,789 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 28,434 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 27,917 | 0 | 0 | 0 | For |
Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 406,410,733 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 2.22% |
| 2 | State Street | 0.42% |
| 3 | BlackRock | 0.27% |
| 4 | Fidelity | 0.26% |
| 5 | TIAA | 0.08% |
| 6 | Equitable | 0.07% |
| 7 | Charles Schwab | 0.07% |
| 8 | Lincoln Financial | 0.05% |
| 9 | Dimensional | 0.05% |
| 10 | Russell Investments | 0.04% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Kinnevik AB (publ) | 3.31% |
| 2 | Mubadala Investment Co PJSC | 3.20% |
| 3 | Novo Holdings A/S | 2.38% |
| 4 | Nikko Asset Management Co., Ltd. | 2.09% |
| 5 | Lingotto Investment Management LLP | 0.90% |
| 6 | State Street | 0.59% |
| 7 | BlackRock | 0.46% |
| 8 | Laurion Capital Management LP | 0.38% |
| 9 | MIC Capital Management UK LLP | 0.34% |
| 10 | Northern Trust | 0.32% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| ARK Investment Management LLC | 37,316,856 | 9.18% | Schedule 13G, filed February 3, 2026 |
| Vanguard Group | 32,287,977 | 7.94% | Form 13F, quarter ended March 31, 2025 |
| BAILLIE GIFFORD & CO | 23,774,972 | 5.85% | Schedule 13G, filed February 5, 2026 |
| BlackRock | 23,506,589 | 5.78% | Form 13F, quarter ended March 31, 2025 |
| Zachary Bogue | 13,628,602 | 3.35% | Proxy statement (DEF 14A), table as of April 21, 2025 |
| State Street | 13,085,258 | 3.22% | Form 13F, quarter ended March 31, 2025 |
| RA Capital Management, L.P. | 7,725,096 | 1.90% | Schedule 13G, filed February 14, 2025 |
| Blake Borgeson | 7,168,054 | 1.76% | Proxy statement (DEF 14A), table as of April 21, 2025 |
| FMR (Fidelity) | 6,846,842 | 1.68% | Form 13F, quarter ended March 31, 2025 |
| Geode Capital | 6,443,980 | 1.59% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 406,410,733 shares outstanding, as reported by RECURSION PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At RECURSION PHARMACEUTICALS INC.'s 2 shareholder meetings in the 2024-2025 proxy season (held November 12, 2024 and June 18, 2025), 301 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,504 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item of the season, voted at the meeting held June 18, 2025 — Advisory vote to approve executive compensation as disclosed in the 2025 Proxy Statement. — RECURSION PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: RECURSION PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 18, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RECURSION PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
RECURSION PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “RECURSION PHARMACEUTICALS (RXRX) 2024-2025 Annual & Special Meetings”, https://proxyvotesnow.com/company/recursion-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.